PMID- 28526540
OWN - NLM
STAT- MEDLINE
DCOM- 20180418
LR  - 20180418
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 243
DP  - 2017 Sep 15
TI  - Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new 
      potential pharmacological target.
PG  - 86-90
LID - S0167-5273(16)34166-3 [pii]
LID - 10.1016/j.ijcard.2017.05.032 [doi]
AB  - BACKGROUND: Empagliflozin is reported to reduce cardiovascular mortality and the 
      rate of hospitalization for heart failure in type 2 diabetic patients with prior 
      cardiovascular events. The mechanisms underlying the cardiac effects of this 
      sodium/glucose transporter 2 (SGT2) inhibitor have not yet been clarified, though 
      a direct action of the drug on the cardiomyocytes could be hypothesized. The aim 
      of the present study is to assess the relative expression of SGLT2 and SGLT1, the 
      two most relevant members of the SGLT family being potentially responsive to 
      empagliflozin, in normal, ischemic and hypertrophic human hearts. METHODS: Tissue 
      biopsies of healthy (n=9), ischemic (n=9) and hypertrophic (n=6) human hearts 
      were analyzed by real time quantitative RT-PCR, confocal immunofluorescence and 
      Western blot techniques. RESULTS: We found no expression of SGLT2 in either 
      normal or pathological conditions, whereas SGLT1 was expressed in normal 
      myocardial tissue and significantly upregulated in ischemia and hypertrophy, in 
      association with increased phosphorylation in activating domains of the 
      intracellular second messengers AMP-activated protein kinase (AMPK), 
      extracellular-signal regulated kinase 1 and 2 (ERK-1/2) and mammalian target of 
      rapamycin (mTOR). CONCLUSIONS: These findings open the possibility that 
      hyperexpressed SGLT1 in cardiomyocytes may represent a potential pharmacological 
      target for cardioprotection.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Di Franco, Alessandra
AU  - Di Franco A
AD  - Endocrinology Unit, Dept. Clinical and Experimental Biomedical Sciences "Mario 
      Serio", University of Florence, Viale G. Pieraccini, 6, Florence, Italy.
FAU - Cantini, Giulia
AU  - Cantini G
AD  - Endocrinology Unit, Dept. Clinical and Experimental Biomedical Sciences "Mario 
      Serio", University of Florence, Viale G. Pieraccini, 6, Florence, Italy.
FAU - Tani, Alessia
AU  - Tani A
AD  - Section of Anatomy and Histology, Dept. Experimental and Clinical Medicine, 
      University of Florence, Largo Brambilla 3, Florence, Italy.
FAU - Coppini, Raffaele
AU  - Coppini R
AD  - Pharmacology Unit, Dept. of Neuroscience, Psychology, Drug Sciences and Child 
      Health, University of Florence, Viale G. Pieraccini, 6, Florence, Italy.
FAU - Zecchi-Orlandini, Sandra
AU  - Zecchi-Orlandini S
AD  - Section of Anatomy and Histology, Dept. Experimental and Clinical Medicine, 
      University of Florence, Largo Brambilla 3, Florence, Italy.
FAU - Raimondi, Laura
AU  - Raimondi L
AD  - Pharmacology Unit, Dept. of Neuroscience, Psychology, Drug Sciences and Child 
      Health, University of Florence, Viale G. Pieraccini, 6, Florence, Italy.
FAU - Luconi, Michaela
AU  - Luconi M
AD  - Endocrinology Unit, Dept. Clinical and Experimental Biomedical Sciences "Mario 
      Serio", University of Florence, Viale G. Pieraccini, 6, Florence, Italy. 
      Electronic address: michaela.luconi@unifi.it.
FAU - Mannucci, Edoardo
AU  - Mannucci E
AD  - Endocrinology Unit, Dept. Clinical and Experimental Biomedical Sciences "Mario 
      Serio", University of Florence, Viale G. Pieraccini, 6, Florence, Italy; 
      Diabetology, Careggi Hospital, Florence, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170509
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (SLC5A1 protein, human)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 1)
RN  - 0 (Sodium-Glucose Transporter 2)
SB  - IM
CIN - Int J Cardiol. 2018 Apr 15;257:37. PMID: 29506735
CIN - Int J Cardiol. 2018 Apr 15;257:38. PMID: 29506737
MH  - Cells, Cultured
MH  - Endothelium, Vascular/metabolism/pathology
MH  - Humans
MH  - Myocardial Ischemia/*metabolism/pathology
MH  - Myocardium/*metabolism/pathology
MH  - Myocytes, Cardiac/*metabolism/pathology
MH  - Sodium-Glucose Transporter 1/*biosynthesis
MH  - Sodium-Glucose Transporter 2/*biosynthesis
OTO - NOTNLM
OT  - Cardiac hypertrophy
OT  - Empagliflozin
OT  - Heart failure
OT  - Ischemic heart disease
OT  - Myocardial disease
OT  - SGLT1
OT  - SGLT2
EDAT- 2017/05/21 06:00
MHDA- 2018/04/19 06:00
CRDT- 2017/05/21 06:00
PHST- 2016/11/28 00:00 [received]
PHST- 2017/05/08 00:00 [accepted]
PHST- 2017/05/21 06:00 [pubmed]
PHST- 2018/04/19 06:00 [medline]
PHST- 2017/05/21 06:00 [entrez]
AID - S0167-5273(16)34166-3 [pii]
AID - 10.1016/j.ijcard.2017.05.032 [doi]
PST - ppublish
SO  - Int J Cardiol. 2017 Sep 15;243:86-90. doi: 10.1016/j.ijcard.2017.05.032. Epub 
      2017 May 9.